Tactical Therapeutics

Tactical Therapeutics is pioneering a novel approach to combat treatment-resistant cancers by inhibiting dysregulated calcium signaling, a key driver of tumor progression and therapy resistance. The company's initial focus is on glioblastoma, one of the most aggressive and difficult-to-treat solid tumors with very limited treatment options and poor patient outcomes. By targeting a fundamental cellular pathway involved in cancer cell survival, Tactical aims to develop a new class of therapeutics that could work alone or in combination with existing treatments. Its success hinges on validating this mechanism in clinical settings and navigating the high-risk development pathway for CNS-active oncology drugs.

First-in-class small molecule inhibitors targeting dysregulated calcium signaling pathways in cancer cells to overcome treatment resistance.

The competitive landscape for calcium signaling inhibitors in oncology is emerging but not yet crowded, with a few biotechs and academics exploring specific ion channel targets. However, Tactical competes broadly with all companies developing therapies for glioblastoma, including those focused on immunotherapy, tumor-treating fields, and other novel mechanisms, all vying for a limited patient pool for clinical trials.